Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes

Diabetes

Volumn 61, Issue 6, 2012, Pages 1592-1598

  Sung, Jia Ying ^a   Park, Susanna B ^b   Liu, Ya Ting ^a   Kwai, Natalie ^c   Arnold, Ria ^c   Krishnan, Arun V ^c   Lin, Cindy S Y ^a,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; NERVE EXCITABILITY; NERVE FIBER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SCORING SYSTEM; TOTAL NEUROPATHY SCORE;

ACTION POTENTIALS; AGED; AXONS; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR NEURONS; MUSCLE, SKELETAL; NEURAL CONDUCTION; POLYNEUROPATHIES; SEVERITY OF ILLNESS INDEX;

EID: 84861884883     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1509     Document Type: Article

References (40)

1. Danaei G, Finucane MM, Lu Y, et al.; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
3. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-824 (Pubitemid 23121981)
4. Pop-Busui R, Lu J, Lopes N, Jones TL; BARI 2D Investigators. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst 2009;14:1-13
5. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003;26:2305-2310 (Pubitemid 36993317)
6. van Schie CH. Neuropathy: mobility and quality of life. Diabetes Metab Res Rev 2008;24(Suppl 1):S45-S51 (Pubitemid 351816709)
7. Turns M. The diabetic foot: an overview of assessment and complications. Br J Nurs 2011;20:S19-S25
8. Khazai NB, Beck GR Jr, Umpierrez GE. Diabetes and fractures: an over-shadowed association. Curr Opin Endocrinol Diabetes Obes 2009;16:435-445
9. Greene D. The pathogenesis and prevention of diabetic neuropathy and nephropathy. Metabolism 1988;37(Suppl. 1):25-29 (Pubitemid 18058181)
10. Sundkvist G, Dahlin LB, Nilsson H, et al. Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance. Diabet Med 2000;17:259-268 (Pubitemid 30266119)
11. Pop-Busui R, Marinescu V, Van Huysen C, et al. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 2002;51:2619-2628 (Pubitemid 34827415)
12. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011;7:573-583
13. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ 3rd, O'Brien PC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999;22:1479-1486 (Pubitemid 29418242)
14. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48:870-880 (Pubitemid 29153089)
15. Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006;12(Suppl. 1):34-41 (Pubitemid 44963609)
16. Dyck PJ, Overland CJ, Low PA, et al.; Cl vs. NPhys Trial Investigators. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve 2010;42:157-164
17. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988;11:21-32 (Pubitemid 18030665)
18. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003;60:108-111 (Pubitemid 36070653)
19. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011;34:2054-2060
20. Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000;23:399-409 (Pubitemid 30126986)
21. Misawa S, Kuwabara S, Ogawara K, Kitano Y, Hattori T. Strength-duration properties and glycemic control in human diabetic motor nerves. Clin Neurophysiol 2005;116:254-258 (Pubitemid 40126928)
22. Krishnan AV, Kiernan MC. Altered nerve excitability properties in established diabetic neuropathy. Brain 2005;128:1178-1187 (Pubitemid 40675471)
23. Bae JS, Kim OK, Kim JM. Altered nerve excitability in subclinical/early diabetic neuropathy: evidence for early neurovascular process in diabetes mellitus? Diabetes Res Clin Pract 2011;91:183-189
24. Dyck PJ, Carter RE, Litchy WJ. Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy. Muscle Nerve 2011;44:340-345
25. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53:1660-1664 (Pubitemid 29530336)
26. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003;61:1297-1300 (Pubitemid 37377562)
27. Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000;123:2542-2551
28. Kuwabara S, Ogawara K, Harrori T, Suzuki Y, Hashimoto N. The acute effects of glycemic control on axonal excitability in human diabetic nerves. Intern Med 2002;41:360-365 (Pubitemid 34746179)
29. Kitano Y, Kuwabara S, Misawa S, et al. The acute effects of glycemic control on axonal excitability in human diabetics. Ann Neurol 2004;56:462-467 (Pubitemid 39319335)
30. + pump dysfunction in diabetic neuropathy. Brain 2008;131:1209-1216
31. Greene DA, Lattimer SA. Impaired energy utilization and Na-K-ATPase in diabetic peripheral nerve. Am J Physiol 1984;246:E311-E318 (Pubitemid 14144230)
32. Zarros A, Liapi C, Galanopoulou P, et al. Effects of adult-onset streptozotocin-induced diabetes on the rat brain antioxidant status and the activities of acetylcholinesterase, (Na(+),K (+))- and Mg(2+)-ATPase: modulation by L-cysteine. Metab Brain Dis 2009;24:337-348
33. + ATPase impairment and experimental glycation: the role of glucose autoxidation. Free Radic Res 1996;24:381-389
34. Zhu X, Eichberg J. 1,2-diacylglycerol content and its arachidonyl-containing molecular species are reduced in sciatic nerve from streptozotocin-induced diabetic rats. J Neurochem 1990;55:1087-1090
35. Zhang W, Yorek M, Pierson CR, Murakawa Y, Breidenbach A, Sima AA. Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat. Int J Exp Diabetes Res 2001;2:187-193
36. Erdoǧan C, Yücel M, Deǧirmenci E, Öz O, Akgün H, Odabaşi Z. Nerve excitability properties in early preclinical diabetic neuropathy. Diabetes Res Clin Pract 2011;94:100-104
37. Takigawa T, Yasuda H, Terada M, et al. Increases in K+ conductance and Ca2+ influx under high glucose with suppressed Na+/K+-pump activity in rat myelinated nerve fibers. Neuroreport 2000;11:2547-2551 (Pubitemid 30622306)
38. Lehning EJ, Doshi R, Isaksson N, Stys PK, LoPachin RM Jr. Mechanisms of injury-induced calcium entry into peripheral nerve myelinated axons: role of reverse sodium-calcium exchange. J Neurochem 1996;66:493-500 (Pubitemid 26036683)
39. Krishnan AV, Lin CS, Park SB, Kiernan MC. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol 2009;89:288-313
40. El-Salem K, Ammari F, Khader Y, Dhaimat O. Elevated glycosylated hemoglobin is associated with subclinical neuropathy in neurologically asymptomatic diabetic patients: a prospective study. J Clin Neurophysiol 2009;26:50-53